Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation
about
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.Developments with experimental and investigational drugs for axial spondyloarthritis.Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes.Tumor Necrosis Factor Alpha Overexpression Induces Mainly Osteoclastogenesis at the Vertebral Site.Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis 'CRP-negative'
P2860
Q33726030-896067A3-909E-4C97-ADE8-5DDEFA98A322Q38611064-CA845F12-2B05-4970-A740-C85BB5ED504DQ38676714-78675C1A-96C8-4D6A-9118-385E55BD9934Q40042219-F443E085-4B0B-4CC7-B704-834F1EF1703DQ40081220-E772650E-223F-4D24-B329-3766FC08448AQ45893661-C8E045B7-BE44-4037-8D5D-1D17D3176D48Q47259944-DA4C3085-5CD0-44BE-B01B-9D54F8CBB195Q47830081-13F1932B-5E02-4446-87B4-6D29E6059B15Q48653605-4853E029-6415-44AC-B69F-7EC4F984115FQ55510543-EE95871A-183A-44C9-A81F-82D6AFE481F1Q58741601-6D309DCF-79E3-4D03-8192-6D934CF0D207
P2860
Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Tumour necrosis factor-α inhib ...... review and economic evaluation
@ast
Tumour necrosis factor-α inhib ...... review and economic evaluation
@en
Tumour necrosis factor-α inhib ...... review and economic evaluation
@nl
type
label
Tumour necrosis factor-α inhib ...... review and economic evaluation
@ast
Tumour necrosis factor-α inhib ...... review and economic evaluation
@en
Tumour necrosis factor-α inhib ...... review and economic evaluation
@nl
prefLabel
Tumour necrosis factor-α inhib ...... review and economic evaluation
@ast
Tumour necrosis factor-α inhib ...... review and economic evaluation
@en
Tumour necrosis factor-α inhib ...... review and economic evaluation
@nl
P2093
P356
P1154
2-s2.0-84958052611
P1476
Tumour necrosis factor-α inhib ...... review and economic evaluation
@en
P2093
Eldon Spackman
Eleftherios Sideris
Gurleen Jhuti
Lesley Kay
Mark Corbett
Marta Soares
Nerys Woolacott
Stephen Palmer
Stephen Rice
P304
1-334, v-vi
P356
10.3310/HTA20090
P407
P5530
P577
2016-02-01T00:00:00Z
P5875
P6179
1071139564